LianBio – accelerating availability of paradigm-shifting medicines for Asian markets

New and dynamic companies are being formed to bridge the gap between global innovation and the China market and accelerate access to innovative new drugs from the US, Europe and elsewhere that address unmet patient needs. LianBio from China is one such company having mission to provide access to the best science-driven therapeutic discoveries to patients in China and major Asian markets.

- Hithaishi C Bhaskar

Asia Pacific (APAC) is witnessing enormous challenges related to accessibility and affordability of healthcare solutions. This is especially evident in China, where regulatory and Intellectual property (IP) reforms, as well as burgeoning consumer demand for innovative drugs are creating favourable market conditions in the world’s one of the largest pharmaceutical market. New and dynamic companies are being formed to bridge the gap between global innovation and the China market and accelerate access to innovative new drugs from the US, Europe and elsewhere that address unmet patient needs.

Investment platforms are providing smart solutions to bring in clinical providers, commercial partners and impactful startups to accelerate drug and therapeutic development to thrive into emerging Asian market. Ventures capitalists assist biopharmaceuticals companies at all stages of development, be it company’s early-stage designing, testing transformative technologies or to commercial-stage companies seeking additional growth. With diversified portfolios, these biopharmaceuticals, medical device and digital health companies focus on significant healthcare needs.